Evaluation of efficacy and safety of adjuvant Pentoxifylline therapy in adults with community acquired pneumonia: An Open label, Randomized-controlled trial. - NI

SARANDEV A T V0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1)At least one acute clinical sign compatible with pneumonia (dyspnea, cough, purulent sputum, crackles)
•2)Infiltrate on chest X-ray or CT scan suggestive of pneumonia
•3)Diagnosis of CAP at or during the 48 hours post-hospital admission.
•4)Informed consent signed by the patient, his/her legally authorized representative.

•1)Patient on invasive mechanical ventilation.
•2)Patients with creatinine clearance less than 30 ml per minute
•3)Patient on vasopressors at the time of inclusion
•4)Any contraindications to the study drug
•5)Patient requiring corticosteroids (except for nebulized corticosteroids) for any reason.
•6)Patient treated with antibiotics for more than 7 days prior to admission.
•7)Suspicion of aspiration or heath care associated pneumonia.
•8)Active tuberculosis
•9)On immunosuppressive therapy or malignancy
•10)Pregnancy or lactating women

发起方

SARANDEV A T V